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EDITORIAL
Personalised medicine for cystic fibrosis: treating the
basic defect
J. Stuart Elborn
THE RIGHT TREATMENT, FOR THE RIGHT PATIENT, AT
THE RIGHT TIME
The concept of personalised or stratified therapies is not a new
one. For centuries, physicians have observed that the manifesta-
tion of a disease and its response to intervention can vary
according to many factors including age, sex, ethnicity, diet and
the type of administered drug [1]. Hippocrates, for example,
observed over 2,000 years ago that patients can respond very
differently to various medications [2].
It wasn’t until 1998, however, that the term ‘‘personalised
therapy’’ was first used [3]. This can be defined as a therapy
prescribed using molecular profiling technologies to tailor the
right therapeutic strategy for the right person at the right time.
The therapy is typically accompanied by a ‘‘companion test’’ or
clinical biomarker to identify responders whilst assessing
therapeutic response.
Personalised medicine is often used synonymously with the
expression ‘‘stratified medicine’’. There are, however, subtle dif-
ferences between both of these terms as illustrated by the patient
therapeutic continuum described by TRUSHEIM et al. (fig. 1) [4].
Most of today’s medical practice is empirical, with drug
development targeted at treating large populations of patients;
an example is non-steroidal anti-inflammatory drugs, which
have high efficacy in almost the entire population (fig. 1).
Other agents, however, may have a significant number of non-
responders, as is the case with selective serotonin-reuptake
inhibitors for the treatment of depression. Identifying and
specifically treating this subpopulation of patients is stratified
medicine [5]. A well-known example is the monoclonal anti-
body trastuzumab, which represents one of the first targeted
adjunctive therapies for the treatment of breast cancer in
patients who overexpress HER2/neu, the gene for human
epidermal growth factor receptor 2 [6].
The most specific level in the patient therapeutic continuum of
care is personalised or individualised medicine. An extreme
example of this is development of a vaccine for an individual
patient. Oncophage and provenge are both examples of
therapeutic ‘‘cancer vaccines’’ for the treatment of renal cell
carcinoma and prostate cancer, respectively [7]. Both therapies
are tailor made to raise a specific immune response against the
molecular profile of the patient’s cancer.
PERSONALISED MEDICINE AND RESPIRATORY
DISEASE
Respiratory medicine is at the forefront of personalised
medicine, as exemplified by recent advances in asthma
research. Asthma, as a complex multifactorial disease, poses
a significant challenge for genomics-led drug discovery. The
disease pathophysiology involves the interaction of multiple
genes with each other, and with a plethora of environmental
factors, such as allergens, pathogens and air pollution [8].
Nevertheless, over the past few years there has been significant
progress in identifying asthma-associated genes, primarily
driven by genome-wide association studies [9, 10]. Gene
expression profiling will not only allow accurate profiling of
responders and non-responders to particular therapies, but
will also aid identification of novel therapeutic targets for drug
discovery. Ultimately, this could lead to asthma management
plans tailored to individual patients.
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FIGURE 1. The spectrum of therapeutic care: from empirical medicine to
personalised medicine. PPI: proton pump inhibitor; SSRI: serotonin reuptake
inhibitor; NSAID: non-steroidal anti-inflammatory drug.
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CYSTIC FIBROSIS AS A PARADIGM FOR PROSPECTIVE
PERSONALISED DRUG DEVELOPMENT
Cystic fibrosis (CF) is an inherited disease affecting the
respiratory, digestive and reproductive systems [11]. The
disease is caused by mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene, colloquially referred
to as the CF gene. When CF was first described in 1938, the
predicted survival age of patients was only 6 months [12].
Over the decades the prognosis has incrementally increased
due to the introduction of multiple therapies that treat the
symptoms of CF (fig. 2). Despite these improvements, how-
ever, the predicted survival age of CF patients was reported as
only 37 yrs as recently as 2009 [12].
CF as a disease area is well positioned to take advantage of
personalised medicine. It is a monogenic disorder (i.e. is the result
of mutation(s) in a specific gene) and has a well-characterised
pathophysiology with clear therapeutic targets [13]. Furthermore,
diagnosis of CF often utilises genetic testing, leading to a high rate
of mutation identification in the CF population [14]. Research into
CFTR gene mutations continues to reveal correlations between
various CFTR genotypes and disease severity [15].
Recently, a first-in-class disease-modifying CF treatment was
approved in the USA and Europe for patients with a specific
mutation in their CFTR gene. The clinical development of this
small molecule CFTR modulator (ivacaftor) serves as a
promising example of how personalised therapies can trans-
form the therapeutic landscape.
This series of articles has been developed based on the
symposium ‘‘Personalized medicine: Treatment advances and
the genetic medical revolution’’, which was held during the
2012 European Respiratory Society Congress in Vienna, Austria.
The articles in this series will discuss the potential impact of
personalised medicine approaches on respiratory medicine in
light of the recent development of CFTR modulators.
HALL [16] will begin by introducing the concepts of persona-
lised medicine and how this approach differs from traditional
treatment management approaches, and provide a number of
examples in the field of oncology before examining recent
salient findings in respiratory medicine. DERICHS [17] will
provide an overview of the genetics and pathophysiology of
CF and how this knowledge is being applied to CF drug
discovery. He will also comment on the various classes of
CFTR mutations and how they can be targeted by CFTR
modulators, as well as briefly examining the proposed
mechanisms of action of CFTR modulators before focusing
on the pre-clinical development of ivacaftor. SERMET-GAUDELUS
[18] will explore the clinical translation of CFTR modulators by
reviewing data from ivacaftor clinical trials in CF patients with
a specific CFTR mutation called G551D, and conclude by
commenting on the potential future impact of CFTR modula-
tors on CF care.
The prospects of developing personalised therapies in the field
of respiratory medicine look promising, as illustrated by the
ivacaftor clinical development programme in CF. Nevertheless,
the challenges faced by researchers developing personalised
therapies remain significant, especially in more complex
polygenetic diseases, such as asthma. Overcoming these
challenges will require collaboration between public bodies,
such as academic institutions, regulatory authorities and clinical
networks, and commercial organisations, such as pharmaceu-
tical and diagnostic companies [19].
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FIGURE 2. Schematic illustration of how the introduction of novel cystic
fibrosis (CF) therapies influenced patient survival over the decades. HTS: high
throughput screening; AZLI: aztreonam for inhalation solution; TIP: tobramycin
inhalation solution.
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